Approval marks CELYSTRA Pharma’s second product approved by Health Canada in nine months and brings a new treatment option for Canadians living with hereditary angioedema.
Illuminating life at the cellular level
Latest News
-
CELYSTRA Pharma at the 25th Annual Market Access Summit in Toronto
Paul Lévesque, President, CEO and Co-Founder of CELYSTRA Pharma, spoke at the 25th Annual Market Access Summit. He discussed launch strategy in Canada amid long approval timelines and global uncertainty.
-
Health Canada Approves DAWNZERA® (donidalorsen) for the Prevention of Hereditary Angioedema Attacks
Approval marks CELYSTRA Pharma’s second product approved by Health Canada in nine months and brings a new treatment option for Canadians living with hereditary angioedema.